The specification and use of 18F-FES PET in breast cancer
Estrogen receptor (ER) is overexpressed in approximately 2/3 of breast cancer patients’ lesions. Noninvasive detection of ER in vivo and dynamic monitoring of ER are crucial for individualized treatment decision-making. 16α-18F-17β-fluoroestradiol (18F-FES) positron emission tomography (PET) has bee...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Editorial Office of China Oncology
2023-08-01
|
| Series: | Zhongguo aizheng zazhi |
| Subjects: | |
| Online Access: | http://www.china-oncology.com/fileup/1007-3639/PDF/1693553447922-717195834.pdf |
| _version_ | 1797694020816732160 |
|---|---|
| author | YANG Zhongyi, XU Xiaoping, WANG Mingwei, ZHANG Yongping, YANG Jianwei, CHEN Yue, XU Wengui, LI Yaming, ZHANG Yingjian, SONG Shaoli |
| author_facet | YANG Zhongyi, XU Xiaoping, WANG Mingwei, ZHANG Yongping, YANG Jianwei, CHEN Yue, XU Wengui, LI Yaming, ZHANG Yingjian, SONG Shaoli |
| author_sort | YANG Zhongyi, XU Xiaoping, WANG Mingwei, ZHANG Yongping, YANG Jianwei, CHEN Yue, XU Wengui, LI Yaming, ZHANG Yingjian, SONG Shaoli |
| collection | DOAJ |
| description | Estrogen receptor (ER) is overexpressed in approximately 2/3 of breast cancer patients’ lesions. Noninvasive detection of ER in vivo and dynamic monitoring of ER are crucial for individualized treatment decision-making. 16α-18F-17β-fluoroestradiol (18F-FES) positron emission tomography (PET) has been used in a variety of preclinical and clinical studies to detect ER expression. However, there is still a lack of technical specifications in China. This technical specification was jointly written by domestic experts who had experience of 18F-FES PET imaging and was formed through consultation based on their own experience and research progress in this field both domestically and internationally. This technical specification introduced the synthesis method and quality control requirements of 18F-FES, recommended its clinical application scenarios, and classified them. In addition, experts’ suggestions were provided throughout the entire process systemically and detailly, including pre-imaging preparation, imaging process, image analysis (normal biological distribution, determination of ER positive and negative, lesion detection, influencing factors, false negative and false positive, report requirements), and the limitations of this imaging technique were proposed. The future application prospects were also discussed. This specification aimed to promote the standardized application of 18F-FES PET in China, achieve repeatability and comparability, and provide important molecular imaging technical support for accurate diagnosis and treatment of breast cancer. |
| first_indexed | 2024-03-12T02:50:58Z |
| format | Article |
| id | doaj.art-1d3b0a03d60d470da8946acd78652583 |
| institution | Directory Open Access Journal |
| issn | 1007-3639 |
| language | English |
| last_indexed | 2024-03-12T02:50:58Z |
| publishDate | 2023-08-01 |
| publisher | Editorial Office of China Oncology |
| record_format | Article |
| series | Zhongguo aizheng zazhi |
| spelling | doaj.art-1d3b0a03d60d470da8946acd786525832023-09-04T00:45:54ZengEditorial Office of China OncologyZhongguo aizheng zazhi1007-36392023-08-0133880180810.19401/j.cnki.1007-3639.2023.08.009The specification and use of 18F-FES PET in breast cancerYANG Zhongyi, XU Xiaoping, WANG Mingwei, ZHANG Yongping, YANG Jianwei, CHEN Yue, XU Wengui, LI Yaming, ZHANG Yingjian, SONG Shaoli01. Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Center for Biomedical Imaging, Fudan University, Shanghai Engineering Research Center for Molecular Imaging Probes, Shanghai 200032, China;2. PET Center, Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China;3. Department of Nuclear Medicine, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China;4. Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China;5. Department of Nuclear Medicine, the Frist Hospital of China Medical University, Shenyang 11000l, Liaoning Province, ChinaEstrogen receptor (ER) is overexpressed in approximately 2/3 of breast cancer patients’ lesions. Noninvasive detection of ER in vivo and dynamic monitoring of ER are crucial for individualized treatment decision-making. 16α-18F-17β-fluoroestradiol (18F-FES) positron emission tomography (PET) has been used in a variety of preclinical and clinical studies to detect ER expression. However, there is still a lack of technical specifications in China. This technical specification was jointly written by domestic experts who had experience of 18F-FES PET imaging and was formed through consultation based on their own experience and research progress in this field both domestically and internationally. This technical specification introduced the synthesis method and quality control requirements of 18F-FES, recommended its clinical application scenarios, and classified them. In addition, experts’ suggestions were provided throughout the entire process systemically and detailly, including pre-imaging preparation, imaging process, image analysis (normal biological distribution, determination of ER positive and negative, lesion detection, influencing factors, false negative and false positive, report requirements), and the limitations of this imaging technique were proposed. The future application prospects were also discussed. This specification aimed to promote the standardized application of 18F-FES PET in China, achieve repeatability and comparability, and provide important molecular imaging technical support for accurate diagnosis and treatment of breast cancer.http://www.china-oncology.com/fileup/1007-3639/PDF/1693553447922-717195834.pdf|breast cancer|positron emission tomography|16α-18f-17β-fluoroestradiol|specification|application |
| spellingShingle | YANG Zhongyi, XU Xiaoping, WANG Mingwei, ZHANG Yongping, YANG Jianwei, CHEN Yue, XU Wengui, LI Yaming, ZHANG Yingjian, SONG Shaoli The specification and use of 18F-FES PET in breast cancer Zhongguo aizheng zazhi |breast cancer|positron emission tomography|16α-18f-17β-fluoroestradiol|specification|application |
| title | The specification and use of 18F-FES PET in breast cancer |
| title_full | The specification and use of 18F-FES PET in breast cancer |
| title_fullStr | The specification and use of 18F-FES PET in breast cancer |
| title_full_unstemmed | The specification and use of 18F-FES PET in breast cancer |
| title_short | The specification and use of 18F-FES PET in breast cancer |
| title_sort | specification and use of 18f fes pet in breast cancer |
| topic | |breast cancer|positron emission tomography|16α-18f-17β-fluoroestradiol|specification|application |
| url | http://www.china-oncology.com/fileup/1007-3639/PDF/1693553447922-717195834.pdf |
| work_keys_str_mv | AT yangzhongyixuxiaopingwangmingweizhangyongpingyangjianweichenyuexuwenguiliyamingzhangyingjiansongshaoli thespecificationanduseof18ffespetinbreastcancer AT yangzhongyixuxiaopingwangmingweizhangyongpingyangjianweichenyuexuwenguiliyamingzhangyingjiansongshaoli specificationanduseof18ffespetinbreastcancer |